Sight Sciences (SGHT) 25th Annual Needham Virtual Healthcare Conference summary

Key conference insights

• Strong engagement at ASCRS highlighted a growing interventional mindset in ophthalmology, with significant interest in both glaucoma and dry eye interventions.

• Unique overlap between interventional glaucoma and dry eye segments is creating synergies in customer and patient engagement.

• Conferences drive leads, training, and sales, with post-event follow-up fueling ongoing growth and market traction.

• Early adopters are driving procedural dry eye adoption, especially in Medicare-dense ophthalmology practices.

• Reimbursement expansion and education are key to scaling procedural interventions in dry eye and glaucoma.

Market opportunity and strategy

• Estimated 19 million diagnosed dry eye patients in the U.S., with 7–8 million moderate to severe cases suitable for intervention.

• Targeting approximately 6,500 ophthalmology practices for dry eye interventions, with future expansion into optometry as commercial coverage grows.

• Commercial payers represent about 70% of the dry eye market, with Medicare accounting for 30%; Medicare prevalence is higher due to age demographics.

• Synergies between glaucoma and dry eye practices are leveraged through cross-selling and collaborative care models.

• Sales force expansion is phased, focusing on high-opportunity states and efficient scaling as reimbursement and market density increase.

Product development and pipeline

• OMNI remains the flagship for interventional glaucoma, with Edge and upcoming Ultra iterations enhancing the portfolio.

• SION serves as an entry-level MIGS device, helping build relationships with new surgeons before transitioning to OMNI.

• Next-generation TearCare and additional interventions in glaucoma and dry eye are in development, with pre-human and animal data showing promise.

• Manufacturing diversification outside China is underway, with new sites expected in 2026 to mitigate risks and maintain strong gross margins.